Retatrutide, a new dual agonist of the GLP-1 binding site and glucose-dependent released polypeptide (GIP) binding site , is exhibiting promising outcomes in preliminary clinical trials . Recent research https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/